The European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) registry was a prospective, observational registry conducted in 21 countries. Patients with unscheduled hospitalizations for AHF (n = 6926) were included: 1304 (18.8%) patients received a combination of intravenous (i.v.) vasodilators and diuretics, 833 (12%) patients received i.v. inotropes and/or vasopressors. Primary endpoint was long-term all-cause mortality. Main secondary endpoints were in-hospital and post-discharge mortality. Adjusted hazard ratio (HR) showed no association between the use of i.v. vasodilator and diuretic and long-term mortality [HR 0.784, 95% confidence interval (CI) 0.596-1.032] nor in-hospital mortality (HR 1.049, 95% CI 0.592-1.857) in the matched cohort (n = 976 paired patients). By contrast, adjusted HR demonstrated a detrimental association between the use of i.v. inotrope and/or vasopressor and long-term all-cause mortality (HR 1.434, 95% CI 1.128-1.823), as well as in-hospital mortality (HR 1.873, 95% CI 1.151-3.048) in the matched cohort (n = 606 paired patients). No association was found between the use of i.v. inotropes and/or vasopressors and long-term mortality in patients discharged alive (HR 1.078, 95% CI 0.769-1.512). A detrimental association with inotropes and/or vasopressors was seen in all geographic regions and, among catecholamines, dopamine was associated with the highest risk of death (HR 1.628, 95% CI 1.031-2.572 vs. no inotropes).
Introduction
Acute heart failure (AHF) represents a gradual or rapid change in heart failure (HF) signs and symptoms, requiring urgent medical therapies. 1, 2 It is the most common cause of emergency department admission. 3 The initial intravenous (i.v.) therapies of AHF have remained practically unchanged in the last decades. Most AHF patients are treated with diuretics and vasodilators, while others may also receive positive inotropes and/or vasopressors (mostly catecholamines). Several of these therapies have been shown to alleviate symptoms, though this did not translate in benefits on outcome. 4 Furthermore, inappropriate use as well as increasing short-term safety concerns have been reported regarding the use of inotropes and/or vasopressors in AHF. 5, 6 Data, often on small samples, have suggested neutral (levosimendan in SURVIVE 7 ) or even increased short-term mortality with the use of catecholamines with positive inotropic effects (ALARM-HF 8 or milrinone in OPTIME-CHF 9, 10 ). Data on long-term safety of these agents, especially in hospital survivors, are scarce. Therefore, the aim of our study was to assess safety, namely long-term mortality, of i.v. cardiovascular agents, including vasodilators, inotropes, and/or vasopressors in AHF.
Methods
The European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) registry was a prospective, observational registry that involved 211 cardiology centres from 21 European and Mediterranean countries. The study design and results have been previously described. 11 Briefly, the ESC-HF-LT registry collected data on 12 440 patients on a one-day-per-week basis between May 2011 and April 2013. Patients were followed up in accordance with the usual practice of the participating centres and had a mandatory follow-up visit at 12 months to collect information on morbidity and mortality. Participation in the ESC-HF-LT registry had been approved by each local institutional review board in accordance with its country's legislation. All participants provided written informed consent.
Patients with unscheduled hospitalizations for AHF were included in this study. Intravenous cardiovascular agents, namely vasodilators, inotropes and/or vasopressors, that were administered during the first 24 hours after admission, were assessed in the present analysis. We retrospectively analysed long-term safety, especially mortality, of these agents. Primary endpoint was long-term all-cause mortality. Secondary endpoints were (i) in-hospital mortality, (ii) post-discharge all-cause mortality, (iii) post-discharge all-cause rehospitalization, and (iv) long-term cardiovascular mortality. 
Statistical analysis
Categorical variables are presented as counts and percentages, and quantitative variables as mean ± standard deviation or median and interquartile range (IQR), as appropriate.
A propensity-based matching approach was used to create a sample of patients receiving a specific treatment and a sample of control patients with similar characteristics, thus allowing comparisons of treatment with reduced bias. More specifically, two separate matched samples were created in AHF patients: one to compare i.v. vasodilators + i.v. diuretics vs. i.v. diuretics alone (see Supplementary material online, Figure S1 ), and one to assess i.v. inotropes and/or vasopressors vs. no i.v. inotropes and/or vasopressors treatment (see Supplementary material online, Figure S2 ).
The propensity score is the probability that a patient with specific baseline characteristics would receive the treatment evaluated conditionally on individual characteristics. We estimated the propensity score using logistic regression, where the dependent variable was the treatment under study.
The independent variables were patient and centre characteristics. All variables with a potential association with the treatment assignment and/or the outcome were used in these models, except if there were more than 10% missing values in the original database. More precisely, patient baseline characteristics used for propensity score development were age, gender, body mass index, primary diagnosis, clinical presentation, previous atrial fibrillation, obesity, diabetes, treatment of hypertension, peripheral vascular disease, chronic obstructive pulmonary disease, chronic kidney disease, liver dysfunction, depression, current malignant (cancer) disease, peripheral hypoperfusion/cold, peripheral oedema, pulmonary rales, New York Heart Association functional class, systolic blood pressure, diastolic blood pressure, heart rate, sodium, beta-blockers and angiotensin-converting enzyme inhibitors (ACEi) pre-admission. Centre characteristics were country.
Propensity-based matching was used to create samples of patients treated by the therapy under study and not treated who were similar in terms of propensity score, i.e. in terms of probability of receiving the therapy. Unmatched observations were discarded, thus leading to possibly non-representative samples of the original database.
A 1:1 matching optimal algorithm without replacement was used, where all treated patients were matched to the closest control within an appropriate range. The success of the propensity score matching was assessed by checking standardized differences between the groups before and after matching, expressed as a percentage. Balancing was considered as successful, if the standardized differences were less than 10% for variables used for propensity score development.
The main endpoint of the study was long-term all-cause mortality. In addition, the secondary endpoints were all-cause in-hospital mortality, all-cause post-discharge death, and post-discharge rehospitalization. Treatment effects were estimated using Cox proportional cause-specific hazards models. Analyses were first performed using the original samples unadjusted and adjusted for characteristics associated with the outcome and other treatments (age, gender, history of HF, coronary artery disease, atrial fibrillation, diabetes, systolic blood pressure at admission, diastolic blood pressure, heart rate, renal function, hyperglycaemia, hyponatraemia) and secondly using the matching sample. Treatment effects were also estimated in different clinically relevant subgroups using Cox model with interaction between treatment and subgroup.
Plots of Kaplan-Meier for time to long-term all-cause mortality in the whole cohort and propensity-score matched cohorts, as well as in-hospital mortality and post-discharge mortality in the matched cohorts were performed. These plots were divided by treatment.
All analyses were performed using SAS statistical software version 9.4 (SAS institute, Inc., Cary, NC, USA).
Results
A total of 6926 AHF patients were included in the study. Median duration of follow-up was 389.0 (366.0-491.0) days. Among hospitalized AHF patients, 1304 received a combination of i.v. vasodilators (mostly nitrates) and i.v. diuretics during the initial AHF management. They were compared to 4083 patients receiving i.v. diuretics alone. Furthermore, a separate analysis was performed with 833 patients who received one or more i.v. inotropes and/or vasopressors. They were compared to 6067 patients who received neither i.v. inotropes, nor vasopressors ( Figure 1) . Figure S3 ).
Combination of i.v. vasodilators and diuretics and outcome
Concerning the secondary endpoints, no association was seen neither in the whole nor in the matched cohort between the use of i.v. vasodilator and diuretic and all-cause in-hospital mortality, all-cause post-discharge death or post-discharge readmission. Kaplan-Meier analysis confirmed those results (Figure 2 ). Long-term cardiovascular mortality was not significantly different between the two treatment groups in the matched cohort (adjusted HR 0.823, 95% CI 0.607-1.116). and after propensity score matching (n = 606 paired-matched patients). Dobutamine was the most used agent (43%) followed by dopamine (25%) and levosimendan (13%). Median duration of i.v. inotrope and/or vasopressor use was 24.0 (IQR 24.0-60.0) hours ( Table 3) . The primary endpoint of long-term all-cause mortality was greater in patients receiving i.v. inotrope and/or vasopressor compared to those who did not, whether analyses were performed in the whole (43.7% vs. 23.2%) or in the matched cohort (39.8% vs. 29.4%). Unadjusted and adjusted HR on the whole or matched cohort are shown in Figure 3 . Using the multivariate Cox regression analysis, adjusted HR for the association between the use of i.v. inotrope and/or vasopressor and long-term all-cause mortality was 1.720 (95% CI 1.498-1.975] in the whole cohort and 1.434 (95% CI 1.128-1.823) in the matched cohort. Adjusted HR for long-term all-cause mortality remained roughly between 1.5 and 2 in all clinically relevant subgroups of the matched cohort (see Supplementary materials online, Figure S4 and Table S1 ) with few positive interactions (age or peripheral hypoperfusion).
Use of i.v. inotropes and/or vasopressors and outcome
Concerning the secondary endpoints, adjusted HR for associations between the use of i.v. inotrope and/or vasopressor and all-cause in-hospital mortality were 3.138 (95% CI 2.432-4.048) in Data are presented as mean ± standard deviation, or number (%). ACEi, angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; BMI, body mass index; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure. Figure 2 Risk of all-cause death in acute heart failure patients receiving intravenous (IV) vasodilators and diuretics (A), or IV inotropes and/or vasopressors (B). Kaplan-Meier analysis for all-cause mortality and the hazard ratios (HR) and 95% confidence intervals in the propensity-score matched cohort for 1-year and in-hospital mortality in patients receiving IV vasodilators (A) and IV inotropes and/or vasopressors (B).
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the whole cohort and 1.873 (95% CI 1.151-3.048) in the matched cohort ( Figure 3) . Adjusted HR for all-cause post-discharge mortality were 1.249 (95% CI 1.059-1.474) in the whole cohort. However, this association became non-significant after propensity score matching (HR Figure S5 Data are presented as mean ± standard deviation, or number (%). ACEi, angiotensin-converting-enzyme inhibitor; ACS, acute coronary syndrome; BMI, body mass index; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HF, heart failure; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . of AHF did not alter long-term clinical outcomes. Notably, this is the first analysis to demonstrate that the use of inotropes and/or vasopressors in AHF was associated with increased long-term risk of all-cause and cardiovascular death throughout different geographic regions.
The ESC-HF-LT registry indicated that only a minority of AHF patients received vasodilators during the initial hospital management. The combination of vasodilators and diuretics had a tendency to lower the risk of mortality compared to diuretics alone. However, statistical significance is diminished due to the smaller sample size. As a result, our study showed neither harmful, nor beneficial associations with clinical outcomes. These findings are consistent with the neutral effect of vasodilators on mortality described in previous studies, 12, 13 in particular a post-hoc analysis of ESCAPE trial, 14 as well as novel agents such as nesiritide in ASCEND-HF 15 and ularitide in TRUE-AHF.
16,17
Our study further showed that the prevalence of the use of inotropes and/or vasopressors in the ESC-HF-LT registry was still common (12%), though lower than in previous studies: the Italian IN-HF Outcome registry (20%, n = 360) 18 and the global ALARM-HF registry (33%, n = 1617). 8 Our study also suggests a rather inappropriate use of inotropes and/or vasopressors, as only a small proportion of patients treated with catecholamines presented with cardiogenic shock and less than half had signs of peripheral hypoperfusion. Despite the widespread use of inotropes, data from controlled trials have failed to demonstrate benefit with these agents. 4,7 -9,19 On the contrary, catecholamines have been associated with increased risk for adverse outcomes. The CardShock study recently demonstrated the association between the use of adrenaline in cardiogenic shock and a striking myocardial injury as well as increased 90-day mortality, thus raising questions about the safety of this treatment. 20 The increasing safety concerns for the use of catecholamines are reflected in current clinical practice guidelines. The recent ESC guidelines for the diagnosis and treatment of acute and chronic HF further restrict the use of inotropic agents to AHF patients only with symptomatic hypotension and hypoperfusion. 21, 22 Our results confirm that the use of inotropes and/or vasopressors in AHF was consistently associated with short-term death, in line with previous studies, including the global ALARM-HF registry. 8 Our study further extended these findings by showing that detrimental effects of inotropes and/or vasopressors on long-term all-cause and cardiovascular mortality were still pronounced several months after AHF episodes and seen in all studied geographic regions. Our study, however, showed the lack of association between inotropes and/or vasopressors and long-term mortality in hospital survivors. This may suggest an immediate rather than prolonged detrimental effect of inotropes and/or vasopressors on clinical outcome. This needs further evaluation.
The present study also indicates that dopamine has an excess mortality compared to other studied inotropes (such as dobutamine and levosimendan). However, our study was not adequately powered to analyse the differences between individual inotropes and/or vasopressors, thus this finding remains to be confirmed in future studies.
. Our study has important clinical implications as it reinforces safety concerns of inotropes and/or vasopressors in AHF. Our results suggest that the recommendation of careful use of i.v. catecholamines in AHF seems wise. Furthermore, it highlights the universal need for safe agents to stabilize and restore haemodynamics in AHF patients. What is more, our study draws attention to the use of dopamine, as it was associated with worse short-and long-term outcomes compared to other inotropes and/or vasopressors.
Limitations
Our study has several limitations. The observational design of our study is subject to selection bias and confounding. Propensity score methodology allowed balancing groups according to variables that were recorded in the ESC-HF-LT registry. This is an especially detailed registry notably with regard to AHF related variables. By matching patients by propensity scores generated from 25 baseline variables, we accounted for most conceivable confounders. Nevertheless, we cannot rule out inaccuracies in registry data or residual unmeasured confounding. Propensity score analysis strengthens our findings but still cannot replace a randomized study design. Since this was a multicentre registry, it should not be overlooked that some centres recorded data differently than others. There was no central committee for the establishment of AHF diagnosis, or to assure that the requirements of enrolment were equally respected in all countries. However, centres and countries were accounted for in the propensity score development. Furthermore, the associations were strong and consistent among the different analyses conducted (unadjusted, adjusted and propensity scoring). Thus, the impact of any one particular centre should be limited in most cases. There is also a certain amount of missing data that may have influenced the results, especially concerning certain markers that reflect disease severity (such as B-type natriuretic peptide and left ventricular ejection fraction). It should also be noted that propensity score does not allow to match patients who have an absolute indication for the use of vasoactive medications, such as cardiogenic shock. The number of patients presenting with cardiogenic shock was small and therefore not sufficient to analyse the impact of vasopressors and inotropes in this subgroup of patients. However, the detrimental association with the use of inotropes and/or vasopressors and mortality remained evident in the subgroup analysis of hypotensive patients as well as patients with a low ejection fraction. Another important limitation of our study is the lack of data on doses of different inotropes. This might be the source of bias as there might be disparities between low and high dose of certain catecholamines, such as dopamine. It should also be noted that there is a difference between levosimendan and other inotropes, because levosimendan can be administered with much less monitoring and does not require an intensive care unit setting. Therefore, this is a potential source of bias. Moreover, the study is also limited by the absence of data on the course of the disease during the first 24 hours of i.v. therapy administration. Post-baseline factors such as clinical worsening during the admission could affect outcomes, and further analyses adjusting for markers of clinical worsening could have strengthened the propensity score analysis.
Conclusions
Our study, based on the ESC-HF-LT registry data, did not confirm any harms or benefits of the use of vasodilators on long-term clinical outcomes. More importantly, observable associations were revealed between the use of inotropes and/or vasopressors and long-term all-cause and cardiovascular death in all geographic regions. We also observed that dopamine had the greatest negative association with mortality among studied inotropes. Because our study does not prove causality, these findings need to be confirmed in the setting of a prospective randomized clinical trial.
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